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Here, we show that as human embryonic stem cells
(ESCs) exit the pluripotent state, NANOG can play
a key role in determining lineage outcome. It has
previously been reported that BMPs induce differen-
tiation of human ESCs into extraembryonic lineages.
Here, we find that FGF2, acting through the MEK-
ERK pathway, switches BMP4-induced human ESC
differentiation outcome to mesendoderm, character-
ized by the uniform expression of T (brachyury) and
other primitive streak markers. We also find that
MEK-ERK signaling prolongs NANOG expression
during BMP-induced differentiation, that forced
NANOG expression results in FGF-independent
BMP4 induction of mesendoderm, and that knock-
down of NANOG greatly reduces T induction. To-
gether, our results demonstrate that FGF2 signaling
switches the outcome of BMP4-induced differentia-
tion of human ESCs by maintaining NANOG levels
through the MEK-ERK pathway.INTRODUCTION
At day 14 in the human embryo, epiblast cells begin to migrate
inward through the primitive streak to formmesoderm and endo-
derm, marking the start of gastrulation. The term ‘‘presumptive
mesendoderm’’ is sometimes used to describe this early-
migrating population of cells, as they are thought to contribute
to either the mesodermal or endodermal germ layer. Studies
from zebrafish embryonic development (Rodaway et al., 1999)
and mouse embryonic stem cells (ESCs) (Gouon-Evans et al.,
2006) support this idea. NODAL, BMP, WNT, and FGF signaling
pathways and transcription factors T,MIXL1, LHX1, and EOMES
are all involved in primitive streak development (Tam and Loebel,
2007). For example, both Xenopus and mouse studies have
demonstrated a critical role for BMP signaling in mesoderm
formation and dorsal-ventral patterning (Jones et al., 1996;
Winnier et al., 1995). However, in human ESC and mouse326 Cell Stem Cell 8, 326–334, March 4, 2011 ª2011 Elsevier Inc.epiblast stem cell studies, BMP4 has been shown to induce
extraembryonic lineage differentiation (Brons et al., 2007;
Xu et al., 2002). The outcome of BMP signaling is context depen-
dent, but exactly why BMP signaling induces extraembryonic
lineage in one context and mesoderm in another has not been
previously explained.
T (brachyury homolog) is a transcription factor expressed in
the nascent mesendoderm and is required for primitive streak
development (Wilkinson et al., 1990). T was first identified from
a mouse strain in which heterozygous carriers exhibit a short-
tail (brachyury) phenotype (Dobrovolskaia-Zavadskaia, 1927).
In mice homozygous null for T, severe abnormalities are
observed from about day 8 of gestation, and death occurs by
day 10 of gestation (Chesley, 1935). The abnormalities observed
result from a lack of cells migrating through the primitive streak,
leading to reduced mesoderm (Yanagisawa et al., 1981). Exper-
iments in Xenopus have shown that injecting FGF2 into the
animal cap induces primitive streak formation and Xbra
(a T homolog) expression (Smith et al., 1991) and that activation
of MAP kinases is required for Xbra induction (Umbhauer et al.,
1995). It has also been shown that overexpression of Xbra in
Xenopus is sufficient to drive mesendoderm formation (Cunliffe
and Smith, 1992). Exactly how MAP kinase activation is linked
to Xbra induction and primitive streak formation in Xenopus is
unclear.
In contrast, FGF2 promotes self-renewal of human ESCs
(Xu et al., 2005), though the downstream effectors of FGF2
signaling responsible for this are not clearly defined. This is partly
due to the complexity of the pathways influenced by FGF
signaling and the varying culture conditions employed by
different laboratories. The majority of the FGF downstream
effectors are expressed in human ESCs at the mRNA level,
and the PI3K-AKT and MEK-ERK downstream pathways are
reportedly active and important for human ESC self-renewal
(Armstrong et al., 2006; Kang et al., 2005). How these down-
stream FGF pathways intersect with the transcriptional regula-
tors of self-renewal and pluripotency is largely unknown, though
blocking FGF signaling causes NANOG expression level to
decline rapidly (Greber et al., 2010; Xu et al., 2008).
Nanog was first identified in mouse ESCs as a pluripotency-
maintaining factor (Chambers et al., 2003; Mitsui et al., 2003),
and more recent work has demonstrated the importance of
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Human NANOG is part of a core transcriptional regulatory
network in ESCs (Boyer et al., 2005) and is capable of enhancing
the frequency of molecular reprogramming of human somatic
cells into pluripotent cells (Yu et al., 2007). NANOG downregula-
tion by RNA interference in human ESCs leads to extraembry-
onic lineage differentiation in serum-containing medium (Hyslop
et al., 2005) and to upregulation of certain neuronal marker genes
in a chemically defined medium with ACTIVIN A and FGF2
supplements (Vallier et al., 2009). Forced expression of NANOG
enables a feeder-independent culture of human ESCs (Darr
et al., 2006). All of these studies support the idea that NANOG
plays a central role in acquiring and maintaining pluripotency.
Here, we show that FGF maintenance of NANOG levels during
BMP-induced differentiation of human ESCs switches lineage
outcome to mesendoderm.
RESULTS
FGF2 Switches the Outcome of BMP4-Induced
Differentiation of Human ESCs
We previously reported that in mouse embryonic fibroblast
(MEF) conditioned medium, BMP4 induced differentiation of
human ESCs to an extraembryonic tissue enriched for tropho-
blast-specific genes (Xu et al., 2002). However, in defined
mTeSRmedium (Ludwig et al., 2006a), we did not detect expres-
sion of hCG or other trophoblast-specific markers after BMP4
addition. Utilizing whole-genome expression microarray anal-
ysis, we found that removal of FGF2 from mTeSR caused upre-
gulation of hCG genes (CGB,CGB5, andCGA) by day 5 of BMP4
treatment; the resulting cells were very similar to those previ-
ously described in conditioned medium. However, with FGF2
present in mTeSR, BMP4 resulted in the upregulation of primitive
streak (T, MIXL1, LHX1, WNT3), endoderm (SOX17, CXCR4),
and mesoderm (TWIST1, FOXF1) marker genes, but not of
hCG or other trophoblast-specific genes (Figure 1A). FOXA2
transcripts were undetectable, and only weak expression of
GSC was observed in the +FGF2+BMP4-treated cells, which is
more characteristic of posterior streak cells. Upregulation of
ectoderm-specific genes was undetectable in either condition.
To investigate the timing of differentiation, we performed two
time course experiments with either high (50 ng/ml) or low
(5 ng/ml) BMP4 in the presence or absence of FGF2 (Figures
1B and S1A–S1C). In both cases, hCG expression was detected
after 96 hr in the FGF2+BMP4 group, while primitive streak
gene expression was detected after 18 hr in the +FGF2+BMP4
group. Most endoderm and mesoderm genes were upregulated
subsequent to the rise of primitive streak genes. Low levels of T
mRNA detected in the FGF2 with low BMP4 group were likely
due to endogenous FGF2 signaling, as an FGF receptor inhibitor
(PD173074) abolished detectable T expression (Figure 1C) in
similar conditions. Compared to treatment with 50 ng/ml
BMP4, 5 ng/ml BMP4 treatment produced a much wider time
frame for the expression of primitive streak marker genes.
Thus, we used 5 ng/ml BMP4 to induce differentiation for subse-
quent experiments. Doses of FGF2 25 ng/ml or higher did not
show significant differences in maintaining the expression level
of NANOG or in inducing T expression after 36 hr of BMP4 addi-
tion (Figure S1D). Since standard mTeSR medium contains100 ng/ml FGF2 (Ludwig et al., 2006a), we maintained that
concentration for the experiments in this study.
In order to determine the percentage of individual cells ex-
pressing T protein, we performed immunostaining and flow
cytometry. Immunostaining data showed that T protein was
present in the nucleus of most cells after 48 hr of +FGF2+BMP4
treatment (Figure 1D). Few T-positive cells were present
after FGF2+BMP4 treatment, even though endogenous FGF
signaling was not blocked in these experiments. Flow cytometry
confirmed a uniform shift to increased T expression from
the FGF2+BMP4 to +FGF2+BMP4 treatments (Figure 1E). It
should be noted that because the IgG for intracellular staining
consistently demonstrated lower signal intensity compared to
that of the anti-T antibody in all cells tested, including un-
differentiated human ESCs, Figure 1E cannot exclude some
low T expression in the FGF2+BMP4-treated cells. Western
blot data confirmed that T protein was not detected from
the FGF2+BMP4-treated cells (Figure S1E). These results
show that treatment of human ESCs in defined conditions with
BMP4 and high concentrations of FGF2 results in a uniform
differentiation of cells expressing the mesendoderm marker T.
MEK-ERK Pathway Is Essential for Mesendoderm
Differentiation
In each of the time points examined before the onset of T expres-
sion,DUSP6was consistently upregulated in the +FGF2+BMP4-
treated cells compared to the FGF2+BMP4-treated cells
(Table S1).DUSP6, also known asMKP3, encodes a cytoplasmic
phosphatase that dephosphorylates and inactivates ERK1/2,
but not ERK5 (Arkell et al., 2008). Dusp6 null mice are viable
and have a higher basal phosphorylation of ERK1/2 with
unchanged levels of phosphorylation of ERK5, p38, or JNK (Mail-
let et al., 2008).DUSP6 expression is induced by phosphorylated
ERK1/2 and functions in a negative feedback loop, regulating
ERK activity (Li et al., 2007). Thus, increased DUSP6 expression
is a reliable indicator of ERK1/2 activity in response to FGF
signaling.
To test whether the inactivation of ERK1/2 blocks T induction,
we overexpressed DUSP6 in human ESCs while using DUSP10
overexpression as a control. DUSP10 (also known as MKP5)
encodes a structurally related phosphatase that dephosphory-
lates p38 and JNK, but not ERK1/2 (Tanoue et al., 1999; Theodo-
siou et al., 1999). Transgene expression was confirmed by
quantitative RT-PCR (Figure 2A). Western blot detecting phos-
phorylated ERK confirmed that overexpressed DUSP6 was
functional. Although significantly reduced, ERK phosphorylation
is not completely blocked byDUSP6 overexpression (Figure 2B).
DUSP6 overexpression suppressed T induction in +FGF2+
BMP4-treated human ESCs, whereas DUSP10 overexpression
had no effect (Figure 2C). Flow cytometry data (Figure 2D)
confirmed that at the protein level, DUSP6 overexpression
reduced T induction. Because ERK1/2 are the targets of
DUSP6 dephosphorylation, these data suggest that ERK1/2
are key components of the FGF-mediated switch to mesendo-
derm differentiation.
To verify the importance of ERK1/2 in mesendoderm induc-
tion, we added chemical inhibitors against different pathways
downstream of FGF signaling to +FGF2+BMP4-treated human
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Figure 1. FGF2 Signaling Switches the Outcome of BMP4-Induced Differentiation of Human ESCs
(A) Microarray data showing expression levels of selected lineage marker genes from H1 cells treated with different concentrations of BMP4 for 5 days, with or
without FGF2. Fold change values, shown in log2 scale, were normalized against data from H1 ESCs grown in mTeSR medium.
(B) Expression levels of selected genes during a 5 ng/ml BMP4 time course, detected by quantitative RT-PCR. Error bars represent standard deviations from
three replicates. mTeSR-cultured H1 ESC control data (red) were set as 1 for each gene, except T, whose expression level was normalized against data from
36 hr +FGF2+BMP4-treated cells.
(C) FGF receptor inhibitor PD173074 inhibited T induction at the 36 hr time point shown by quantitative RT-PCR analysis. Average expression level from +FGF2+
BMP4 group was set as 1 for each gene.
(D) T protein detected by immunostaining. Top row, DAPI nuclei staining; bottom row, FITC channel showing T staining. Scale bar: 0.1 mm.
(E) Flow cytometry data revealed a uniform shift from FGF2+BMP4 population (shaded gray) to +FGF2+BMP4 population (solid black) for T staining.
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Figure 2. MEK-ERK Pathway Is Required for Mesendoderm Induction
(A) Quantitative RT-PCR analysis confirmed transgene expression in DUSP6- and DUSP10-overexpressing cells. Messenger RNA levels were normalized to
those from the nontransfected human ESCs. Error bars represent standard deviations from three replicates.
(B) DUSP6 overexpression reduced ERK phosphorylation compared to nontransfected H1 ESCs, detected by western blot.
(C and D) DUSP6 overexpression suppressed the induction of T upon +FGF2+BMP4 treatment, confirmed by both quantitative RT-PCR (C) and flow cytometry
(D). mRNA levels were normalized to those of the nontreated control cells in (C).
(E and F) Flow cytometry and immunostaining for T induction with inhibitors. FGF receptor inhibitor PD173074 andMEK inhibitor U0126 blocked the induction of T
upon +FGF2+BMP4 treatment, while other inhibitors (SB203580 against p38, SP600125 against JNK, and LY294002 against PI3K) failed to block T induction.
Scale bar: 0.1 mm in (F).
(G) Only constitutively activatedMEK1mutant (MAP2K1-CC) upregulated T expression in the FGF2+BMP4 condition compared to wild-typeMEK1 (MAP2K1-
W1) control and EGFP control. A single plasmid with doxycycline-inducible elements was used to express transgenes in H9 cells. mRNA levels were normalized
against those from EGFP control in DOX condition.
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induction, while inhibitors of other downstream pathways
(GF109203X against PKC, SP600125 against JNK, LY294002
against PI3K, and SB203580 against p38) had no effect. Also,
we induced the expression of a constitutively activated MEK1
(MAP2K1) mutant in H9 cells in the FGF2+BMP4 condition
and found significant T upregulation by real-time quantitative
PCR compared to the wild-type MAP2K1 and EGFP controls
(Figure 2G). Together, these findings demonstrate that the
MEK-ERK pathway is essential for the FGF-mediated switch in
BMP4-induced differentiation.
FGF2 Prolongs NANOG Expression during BMP4
Treatment, Resulting in Mesendoderm Differentiation
In examining the time course of POU5F1, SOX2, and NANOG
expression during FGF2+BMP4 and +FGF2+BMP4 treat-
ments, we noticed that though the timing of SOX2 downregula-
tion was similar in the presence or absence of FGF2, NANOG
or POU5F1 downregulation was delayed considerably with
FGF2 present (Figures 1B and S1C). Downregulation of
POU5F1 did not begin until the maximum induction of T, even
in the absence of FGF2, suggesting that POU5F1 is unlikely to
contribute to the FGF2 switch. Further, although NANOG
expression was prolonged in the presence of FGF2, transcript
levels eventually decreased, closely paralleling the downregula-
tion of T. When ERK activity was suppressed by DUSP6 overex-
pression during BMP4 treatment, or when MEK was inactivated
by the U0126 inhibitor, FGF2 did not prolongNANOG expression
(Figures S3A and S3B), suggesting that maintenance of NANOG
by FGF2 requires ERK.
Considering the temporal relationship between T and NANOG
during BMP4 treatment, we hypothesized that the maintenance
of NANOG by FGF signaling was directly related to the induction
and eventual downregulation of T. To test this, we used lentiviral
vectors to express NANOG constitutively in human ESCs,
followed by treatment with +FGF2+BMP4 and FGF2+BMP4.
These conditions resulted in T induction, even in the absence
of FGF2 (Figures 3A and 3B). In addition, we found that expres-
sion of T was prolonged in cells overexpressing NANOG.
Although T expression normally peaked at 36–48 hr at the
mRNA level (48–72 hr at the protein level) and then declined, in
cells constitutively expressing NANOG, T was still elevated at
5 days (Figure 3C). Western blot data revealed that the total
NANOG protein level was not increased by lentiviral overexpres-
sion (Figure S3C). Instead, the overall NANOG protein was main-
tained around the same level, even under the FGF2+BMP4
condition, where it would normally be significantly reduced.
Since long-term NANOG knockdown reportedly induces extra-
embryonic lineage differentiation, we simultaneously introduced
NANOG siRNA and treated cells with BMP4 to investigate the
short-term effect of NANOG knockdown on T expression.
Compared to control cells after 36 hr of treatment, NANOG
siRNA-treated cells lost around 80% of endogenous NANOG
mRNA and had significantly less T induction from +FGF2+BMP4
condition (Figure 3D). The knockdown data showed thatNANOG
contributes to successful T induction. Taken together, our
results suggest that NANOG is a critical downstream target of
FGF signaling responsible for switching BMP4-induced differen-
tiation of human ESCs to mesendoderm.330 Cell Stem Cell 8, 326–334, March 4, 2011 ª2011 Elsevier Inc.DISCUSSION
This study suggests that NANOG, in addition to its role in the
initiation and maintenance of pluripotency, is involved in mesen-
doderm specification. Unlike the inner cell mass, later expression
of Nanog in the primitive ectoderm is nonuniform. In situ hybrid-
ization data demonstrate that high Nanog expression in the egg
cylinder-stage mouse embryo is restricted to the site of the
presumptive streak and is later restricted to the region of the
streak itself (Hart et al., 2004). As cellsmigrate through the streak,
Nanog is downregulated. Itwas therefore suggested thatNanog’s
highly restricted expression pattern is consistent with a role in
pattern formation. Because Nanog null embryos lack epiblast,
the involvement ofNanog in later primitive streak formation could
not be examined in those null embryos (Mitsui et al., 2003).
More recently, Nanog null mouse ESCs have been success-
fully generated, and unexpectedly, these ESCs propagated for
long periods and contributed to all three germ layers in chimeras
(Chambers et al., 2007). If Nanog’s role is conserved in mouse
and human development—and this is not yet clear—these
results suggest that there is not an absolute requirement for
Nanog for the induction of primitive streak genes. In this context,
results from our work and earlier mouse ESC works are more
consistent with a protective effect of Nanog, where Nanog
prevents pluripotent stage cells from responding to spurious
signals that would otherwise induce them to inappropriate line-
ages. In our case, it is not clear why BMP signaling induces the
expression of trophoblast genes in human ESCs that otherwise
appear epiblast-like, as epiblast cells in the mouse do not
contribute to trophoblast. It is possible that trophoblast dif-
ferentiation in our experiments reflects real species-specific
differences in lineage specification, but it is also possible that it
represents an in vitro effect in response to a nonphysiological
signaling context. Our results may then simply reflect a wider
role for NANOG in buffering against signaling noise that would
otherwise result in inappropriate differentiation outcomes.
Our results demonstrated a positive effect of NANOG on T
expression, but the mechanism connecting the two remains
unknown. Preliminary ChIP-seq data failed to detect significant
NANOG binding in the T locus region, and ChIP-PCR data (Fig-
ure S3E) did not show significant binding at a published putative
NANOG binding site 4.6 kb upstream of the transcriptional start-
ing site of T (Boyer et al., 2005). This suggests that NANOGmay
not directly regulate T expression. Our findings seem to differ
from a previous mouse ESC study, which suggests that by
binding to Smad1, Nanog blocks T induction fromBMP signaling
(Suzuki et al., 2006). However, mouse and human ESCs respond
differently to BMP signaling, since BMPs promote the self-
renewal of mouse ESCs (Ying et al., 2003) but induce differenti-
ation of human ESCs. These apparent species differences might
be related to the differences between the two cell states, as it is
currently thought that mouse ESCs closely resemble inner cell
mass cells, but human ESCs more closely resemble epiblast
cells (Brons et al., 2007; Tesar et al., 2007). In addition, the block-
ing effect of Nanog on T in the Suzuki study was supported by
a luciferase assay based on 396 bp and 204 bp regions upstream
of the mouse T promoter. These regions may not include regula-
tory elements further upstream that might be used differently in
inner cell mass versus epiblast cells.
Figure 3. NANOG Substitutes for the Requirement of FGF2 in Switching the Outcome of BMP4-Induced Differentiation
(A) Constitutively NANOG-expressed cells induced T expression after 36 hr of FGF2+BMP4 treatment, detected by quantitative RT-PCR. Error bars represent
standard deviations from three replicates. mRNA levels of T and NANOGwere normalized against +FGF2+BMP4-treated H1 cells and mTeSR-cultured H1 cells,
respectively.
(B) MostNANOG-overexpressed cells were T positive, detected by flow cytometry at 48 hr of BMP4 treatment in both +FGF2 andFGF2 groups. Nontreated H1
ESCs served as negative control (shaded gray). The nontransduced ESC control panel is the same as in Figure 2D, since the data were from the same set of
experiment with the same control samples.
(C) NANOG-overexpressing cells had an extended T expression time window at day 5 of differentiation. NANOG-overexpressing cells cultured in mTeSR were
included as negative control (shaded gray).
(D)NANOG knockdown by siRNA reduced T expression level at 36 hr from+FGF2+BMP4-treated cells. siRNAswere introduced at the same timewhen cells were
treated with BMP4. 0.1 mM PD173074 was used to block endogenous FGF signaling in the FGF2+BMP4 condition in all subpanels in this figure.
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Figure 4. SimplifiedModel for theMechanism of the FGF2 Switch on
BMP4-Induced Differentiation Outcomes
Arrow represents activation or induction, dashed arrow represents indirect
activation with multiple steps involved, hammer-ended line represents in-
hibition, and arrow with question mark represents induction with mechanism
undiscovered. Inhibitors that could block T induction in +FGF2+BMP4 condi-
tion are highlighted in red.
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derm differentiation of human ESCs (Zhang et al., 2008).
Although no exogenous FGF was used in that study, differentia-
tionwas induced from human ESCs cultured inMEF-conditioned
medium, which could act as a source of a variety of growth
factors, including FGF. This could explain the requirement for
only short-term BMP exposure, as it is possible that the endog-
enous FGF was not enough to sustain NANOG and a meso-
dermal fate with longer exposure.
Precisely how the MEK-ERK pathway regulates NANOG
expression remains unknown. A candidate link from MEK-ERK
to NANOG might be SMAD2/3, as recent reports suggested
direct regulation of NANOG by SMAD2/3 binding on the
promoter region (Greber et al., 2008; Vallier et al., 2009;
Xu et al., 2008). Both SMAD2/3 and SMAD1/5/8 pathways
were reportedly required for mesendoderm differentiation, and
FGF2 appeared to sustain SMAD2/3, activating TGF-b ligand
expression (Greber et al., 2008). Consistent with their findings,
our data showed that mesendoderm differentiation was inhibited
in +FGF2+BMP4 condition when SMAD2/3 pathway was
blocked by SB431542 (Figure S1I) and that NODAL expression
was better maintained in the presence of FGF2 during BMP4-
induced differentiation (Figures S1A and S1B). Also, the MEK-
ERK pathway is capable of modulating SMAD signaling through
phosphorylation of the linker region of various SMAD proteins
(Kretzschmar et al., 1997; Matsuura et al., 2005). However, the
link between MEK-ERK and NANOG expression might be
indirect. For example, the dominant early phenotypic effect on
undifferentiated human ESCs of FGF2 withdrawal is a slowed
proliferation (Ludwig et al., 2006b). Thus, it is possible that the
level of NANOG is related to cell-cycle progression. A causal
link between cell-cycle progression and NANOG expression is
unfortunately difficult to test, as cell-cycle inhibitors generally
result in the apoptosis of human ESCs.
In conclusion, we demonstrate that a mesendodermal
outcome of BMP4-induced human ESC differentiation depends
on FGF signaling, that MEK-ERK is the relevant downstream
pathway involved, and that NANOG is a key transcription factor
responsible for determining this outcome in our culture con-
ditions (Figure 4). These findings are particularly important,
as they demonstrate that NANOG is not only involved in the
establishment and maintenance of pluripotency, but can serve
a role in determining lineage outcome as cells exit the pluripotent
state.EXPERIMENTAL PROCEDURES
Cell Culture and Reagents
H1, H9, and H14 human ESCs were cultured in mTeSR (Ludwig et al., 2006a)
on Matrigel (BD Biosciences, Bedford, MA). Cells were karyotyped using
G-banding chromosome analysis prior to experiments. Low-passage (<50)
ESCs were dissociated by TrypLE (Invitrogen) and seeded at the density
of 4 3 104/cm2 for all experiments. To induce differentiation, human
BMP4 (R&D Systems, Minneapolis, MN) was added from 0 hr time point,
when dissociated single cells were plated, and was maintained in medium
thereafter.Lentiviral Transduction
The lentiviral vector and packaging of the virus were as described in Yu et al.,
2007. Detailed methods are included in the Supplemental Information.332 Cell Stem Cell 8, 326–334, March 4, 2011 ª2011 Elsevier Inc.Knockdown by siRNA
NANOG ON-TARGETplus SMARTpool siRNA and negative control siRNA
were purchased from Dharmacon, Inc. (Lafayette, CO). siRNA transfection
mixture was prepared according to manufacturer’s instructions and intro-
duced at the same time BMP4 was added to the cell culture. Cells were
collected for RNA extraction after 36 hr of treatment.Inducible MAP2K1 Expression
Wild-type and a constitutively activeMAP2K1were PCR cloned from plasmids
pENTR1A-W1 and pENTR1A-CC2, developed by Paul A. Khavari’s lab (Scholl
et al., 2004). Genes were placed under the control of pTight promoter in
a vector that contains the rtTA-expressing cassette and a puromycin-resistant
element. Elements of the doxycycline-inducible system were cloned from
plasmids purchased from Clontech (Mountain View, CA). Vectors were in-
troduced into EBNA1-expressing H9 cells with the help of FuGENEHD (Roche,
Indianapolis, IN). Puromycin (1 ng/ml) was used to select positive cells 2 days
after transfection. Surviving cells were individualized with TrypLE and plated
into FGF2+BMP4 medium to initiate differentiation for 48 hr in the presence
or absence of doxycycline (0.5 mg/ml).Immunostaining
Adherent cells were washed three times with PBS before being fixed in 2%
paraformaldehyde for 20 min at room temperature, then blocked and permea-
bilized in PBS with 0.3% Triton X-100, 10% normal horse serum, and 1%BSA
at room temperature for 30 min. Cells were then incubated with 0.2 mg/ml of
anti-T antibody (R&D Systems) in PBS with 0.2% BSA and 0.01% Triton
X-100 at 4C overnight followed by FITC-conjugated anti-goat IgG in dark at
room temperature for 1 hr. Cells were washed with PBS containing 0.1%
BSA and 0.01% Triton X-100 three times between each step. Vectashield
mounting medium for fluorescence with DAPI (Vector Laboratories, Burlin-
game, CA) was added before visualizing and taking photos under the
microscope.
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Cells were individualized by Trypsin-EDTA (Invitrogen), fixed in 2% parafor-
maldehyde for 20 min at room temperature, and permeabilized in 90% meth-
anol at 20C overnight. Cells were resuspended in PBS with 2% FBS and
0.1% sodium azide (FACS buffer) and later blocked with PBS with 0.3% Triton
X-100 and 2%BSA at room temperature for 30min. Anti-T antibody (0.5 mg/ml;
R&D Systems) or goat IgG (0.5 mg/ml; Santa Cruz Biotechnology, Santa Cruz,
CA) was added in FACS buffer with 0.01% Triton X-100 at 4C overnight,
followed by FITC-conjugated anti-goat IgG antibody in dark at room tempera-
ture for 1 hr. Between each step, cells were washed with FACS buffer three
times. A PE-conjugated anti-T antibody from R&D Systems was later used in
this study at 1:400 dilutions. Cells were analyzed on a FACSAria flow cytome-
ter (BDIS, San Jose, CA) using FACSDiva Software. Final data were prepared
in FlowJo 6.3 software (Tree Star, Ashland, OR).
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